Nutritional Supplement

Glucosamine for Sports & Fitness

Glucosamine

Possible Deficiencies

A glucosamine deficiency in humans has not been reported.

Side Effects

GS may cause mild and reversible gastrointestinal side effects in some cases. In one trial, people with peptic ulcers and those taking diuretic drugs were more likely to experience such side effects.37

In a preliminary study, glucosamine supplements appeared to raise intraocular (eyeball) pressure by an average of about 3 mm Hg in people who had elevated intraocular pressure or a certain type of glaucoma (open-angle glaucoma).38 Therefore, individuals who have, or are at risk of developing, glaucoma should be monitored by a doctor if they wish to take glucosamine.

Animal research has raised the possibility that glucosamine could contribute to insulin resistance.39,40 This effect might theoretically result from the ability of glucosamine to interfere with an enzyme needed to regulate blood sugar levels.41 However, available evidence does not suggest that taking glucosamine supplements will trigger or aggravate insulin resistance or high blood sugar.42,43 Two large, 3-year controlled trials found that people taking GS had either slightly lower blood glucose levels or no change in blood sugar levels, compared with people taking placebo.44,45 Until more is known, people taking glucosamine supplements for long periods may wish to have their blood sugar levels checked; people with diabetes should consult with a doctor before taking glucosamine and should have blood sugar levels monitored if they are taking glucosamine.

In 1999 the first case of an allergic reaction to oral GS was reported.46 Allergic reactions to this supplement appear to be rare.

References

1. Reginster JY, Deroisy R, Rovati L, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.

2. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23.

3. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75 [review].

4. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-30.

5. Braham R, Dawson B, Goodman C. The effect of glucosamine supplementation on people experiencing regular knee pain. Br J Sports Med 2003;37:45-9.

6. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucoseamine sulfate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982;3:157-68.

7. Giordano N, Nardi P, Senesi M, et al. The efficacy and safety of glucosamine sulfate in the treatment of gonarthritis. Clin Ter 1996;147:99-105.

8. D'Ambrosio E, Casa B, Bompani G, et al. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981;2(8):504­8.

9. Crolle G, DiEste E. Glucosamine sulfate for the management of arthrosis. Curr Ther Res 1980;7:104-9.

10. Qiu GX, Gao SN, Giacovelli G, et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung 1998;48:469-74.

11. Reichelt A, Förster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. Arzneimittelforschung 1994;44:75-80.

12. Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo­controlled double­blind investigation. Clin Ther 1980;3:260-72.

13. Vaz AL. Double­blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in out­patients. Curr Med Res Opin 1982;8:145-9.

14. Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980;7(2):110-4.

15. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005;39:1080-7.

16. Rindone RP. Randomized controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-4.

17. Wilkens P, Scheel IB, Grundnes O, et al. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA 2010;304:45-52.

18. Reginster JY, Deroisy R, Rovati L, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.

19. Nakamura H, Masuko K, Yudoh K, et al. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int 2007;27:213-8.

20. Morrison LM, Murata K. Absorption, distribution, metabolism and excretion of acid mucopolysaccharides administered to animals and patients. In: Morrison LM, Schjeide OA, Meyer K. Coronary heart disease and the mucopolysaccharides (glycosaminoglycans). Springfield: Charles C. Thomas, 1974, 109–27.

21. Denuziere A, Ferrier D, Damour O, et al. Chitosan-chondroitin sulfate and chitosan-hyaluronate polyelectrolyte complexes: biological properties. Biomaterials 1998;19:1275-85.

22. McCarty MF. Glucosamine for wound healing. Med Hypotheses 1996;47:273-5 [review].

23. Glade MJ. Polysulfated glycosaminoglycan accelerates net synthesis of collagen and glycosaminoglycans by arthritic equine cartilage tissues and chondrocytes. Am J Vet Res 1990;51:779-85.

24. Prudden JF, Wolarsky ER, Balassa L. The acceleration of healing. Surg Gynecol Obstet 1969;128:1321-6 [review].

25. Bucci L. Nutrition applied to injury rehabilitation and sports medicine. Boca Raton, FL: CRC Press, 1995, 193.

26. Sprengel H, Franke J, Sprengel A. Personal experiences in the conservative therapy of patellar chondropathy. Beitr Orthop Traumatol 1990;37:259–66 [in German].

27. Lysholm J. The relation between pain and torque in an isokinetic strength test of knee extension. Arthroscopy 1987;3:182–4.

28. Ziegler R, Rau R. Conservative or operative treatment for chondropathia patellae? Beitr Orthop Traumatol 1980;27:201–11 [in German].

29. Böhmer D, Ambrus P, Szögy A, et al. Treatment of chondropathia patellae in young athletes with glucosamine sulfate. In: Bachl N, Prokop L, Suckert R, eds. Current topics in sports medicine. Vienna: Urban & Schwarzenberg, 1984, 799.

30. Danczak E. Glucosamine and plant lectins in autistic spectrum disorders: an initial report on 6 children with uncontrolled diarrhoea. J Nutr Environ Med2004;14:327-330.

31. Danczak E. Glucosamine and plant lectins in autistic spectrum disorders: an initial report on 6 children with uncontrolled diarrhoea. J Nutr Environ Med2004;14:327-330.

32. Swinburne LM. Glucosamine sulphate and osteoarthritis. Lancet2001;357:1617 [Letter].

33. Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo­controlled double­blind investigation. Clin Ther 1980;3:260-72.

34. Vaz AL. Double­blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in out­patients. Curr Med Res Opin 1982;8:145-9.

35. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002;29:2407-9.

36. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-30.

37. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucoseamine sulfate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982;3:157-68.

38. Murphy RK, Ketzler L, Rice RD, et al. Oral glucosamine supplements as a possible ocular hypertensive agent. JAMA Ophthalmol 2013;131:955–7.

39. Virkamaki A, Daniels MC, Hamalainen S, et al. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance in multiple insulin sensitive tissues. Endocrinology 1997;138:2501-7.

40. Rossetti L, Hawkins M, Chen W, et al. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest 1995;96:132-40.

41. Barzilai N, Hawkins M, Angelov I, et al. Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production. Diabetes 1996;45:1329-35.

42. Russell AI, McCarty MF. Glucosamine in osteoarthritis. Lancet 1999;354:1641; discussion 1641-2 [letters].

43. Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes 2006;55:3142-50.

44. Rovati LC, Annefeld M, Giacovelli G, et al. Glucosamine in osteoarthritis. Lancet 1999;354:1640; discussion 1641-2.

45. Reginster JY, Deroisy R, Rovati L, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.

46. Matheu V, Bracia Bara MT, Pelta R, et al. Immediate-hypersensitivity reaction to glucosamine sulfate. Allergy 1999;54:643-50.

Copyright © 2024 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2024.